Premium
Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type 1
Author(s) -
Shugars DC,
Sauls DL,
Weinberg JB
Publication year - 1997
Publication title -
oral diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.953
H-Index - 87
eISSN - 1601-0825
pISSN - 1354-523X
DOI - 10.1111/j.1601-0825.1997.tb00379.x
Subject(s) - slpi , infectivity , peripheral blood mononuclear cell , protease inhibitor (pharmacology) , virology , saliva , protease , virus , biology , immunology , in vitro , monocyte , microbiology and biotechnology , enzyme , inflammation , viral load , biochemistry , antiretroviral therapy
Saliva contains factors that inhibit infection with the human immunodeficiency virus type 1 (HIV‐1) in vitro. One of these factors was recently identified as secretory leukocyte protease inhibitor (SLPI), a salivary protein which blocked HIV‐1 infectivity of monocytes and primary T cells at physiologic concentrations ( J Clin Invest 1995; 96: 456). Here, we confirm and extend the original report by demonstrating that SLPI protects primary monocytes and peripheral blood mononuclear cells against infection with HIV‐1 Ba‐L, IIIB and NL4‐3. Thus, SLPI may provide a natural barrier against oral transmission of HIV‐1.